The Moses H. Cone Memorial Hospital
- Type
- Teaching hospital
- Where
- Greensboro, NC
- Medicare CCN
- 340091
- Received
- $1,301,834 in 441 records, 2021 ($81,140 general, $1,220,693 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit: MOSES H CONE MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 54 | $81,140 |
| 2021 | Research payment | 387 | $1,220,693 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 387 | $1,220,693 |
| Debt forgiveness | 20 | $45,231 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 25 | $17,790 |
| Long term medical supply or device loan | 2 | $10,621 |
| Space rental or facility fees (teaching hospital only) | 5 | $7,400 |
| Charitable Contribution | 1 | $52 |
| Gift | 1 | $45 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Medtronic, Inc. | $19,505 | Research payment | In-kind items and services | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2021 |
| 2021-12-31 | Edwards Lifesciences Corporation | $5,325 | Long term medical supply or device loan | In-kind items and services | HemoSphere Device, Hemodynamic Monitoring | 2021 | |
| 2021-12-31 | Edwards Lifesciences Corporation | $5,296 | Long term medical supply or device loan | In-kind items and services | HemoSphere Device, Hemodynamic Monitoring | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $867 | Research payment | Cash or cash equivalent | Eclipse Treatment Planning System for External Beam Radiation Therapy Device, Oncology | 2021 | |
| 2021-12-31 | AstraZeneca UK Limited | $9 | Research payment | In-kind items and services | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo | 2021 | |
| 2021-12-29 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-12-22 | Novartis Pharmaceuticals Corporation | $17,907 | Research payment | Cash or cash equivalent | LEQVIO Drug, CARDIOVASCULAR | AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISI | 2021 |
| 2021-12-22 | Gilead Sciences, Inc. | $1,173 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2021 | |
| 2021-12-22 | Johnson & Johnson Health Care Systems Inc. | $205 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-15 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $75 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $75 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | $75 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-10 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-12-09 | Medtronic, Inc. | $130 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2021 |
| 2021-12-08 | CSL Behring | $8,097 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-12-08 | Daiichi Sankyo Inc. | $5,833 | Research payment | Cash or cash equivalent | SAVAYSA Drug, Thrombosis | ENVISAGE | 2021 |
| 2021-12-08 | Daiichi Sankyo Inc. | $2,500 | Research payment | Cash or cash equivalent | SAVAYSA Drug, Thrombosis | ENVISAGE | 2021 |
| 2021-12-08 | Daiichi Sankyo Inc. | $1,000 | Research payment | Cash or cash equivalent | SAVAYSA Drug, Thrombosis | ENVISAGE | 2021 |
| 2021-12-08 | Daiichi Sankyo Inc. | $925 | Research payment | Cash or cash equivalent | SAVAYSA Drug, Thrombosis | ENVISAGE | 2021 |
| 2021-12-08 | Daiichi Sankyo Inc. | $875 | Research payment | Cash or cash equivalent | SAVAYSA Drug, Thrombosis | ENVISAGE | 2021 |
| 2021-12-08 | Daiichi Sankyo Inc. | $530 | Research payment | Cash or cash equivalent | SAVAYSA Drug, Thrombosis | ENVISAGE | 2021 |
| 2021-12-08 | Daiichi Sankyo Inc. | $500 | Research payment | Cash or cash equivalent | SAVAYSA Drug, Thrombosis | ENVISAGE | 2021 |
| 2021-12-08 | CSL Behring | $150 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-12-03 | LivaNova USA, Inc. | $2,930 | Research payment | Cash or cash equivalent | VNS - Vitaria Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2021 |
| 2021-12-01 | Tandem Diabetes Care, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-12-01 | Boehringer Ingelheim International GmbH | $160 | Research payment | In-kind items and services | Empagliflozin for prevention of HHF and death after an AMI | 2021 | |
| 2021-11-30 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,253 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-11-30 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-11-29 | CSL Behring | $23,977 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-11-29 | CSL Behring | $850 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-11-24 | Boehringer Ingelheim International GmbH | $9,928 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-11-22 | Hill-Rom Company, Inc | $589 | Debt forgiveness | Cash or cash equivalent | The Vest System 205 Acute Care Device, Airway Clearance Device | 2021 | |
| 2021-11-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $343 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-22 | Esperion Therapeutics, Inc. | $75 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-18 | CSL Behring | $90 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-11-17 | Gilead Sciences, Inc. | $1,173 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2021 | |
| 2021-11-11 | Surmodics, Inc. | $377 | Research payment | Cash or cash equivalent | SurVeil Device, drug-coated balloon | TRANSCEND | 2021 |
| 2021-11-05 | LivaNova USA, Inc. | $4,580 | Research payment | Cash or cash equivalent | VNS - Vitaria Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2021 |
| 2021-11-02 | CVRx, Inc. | $35,000 | Research payment | In-kind items and services | Barostim Neo System Device, Heart Failure and Hypertension | 2021 | |
| 2021-11-01 | Boehringer Ingelheim International GmbH | $2,284 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-10-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,253 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-10-26 | CSL Behring | $750 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-10-26 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-10-26 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-10-26 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $343 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $343 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $75 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-21 | Esperion Therapeutics, Inc. | $75 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-19 | CVRx, Inc. | $28,000 | Research payment | In-kind items and services | Barostim Neo System Device, Heart Failure and Hypertension | 2021 | |
| 2021-10-18 | CVRx, Inc. | $9,841 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2021 | |
| 2021-10-18 | Johnson & Johnson Health Care Systems Inc. | $3,889 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-10-13 | CSL Behring | $22,712 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-10-13 | CSL Behring | $950 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-10-11 | Medtronic, Inc. | $3,840 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Stroke AF | 2021 |
| 2021-10-06 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-09-30 | SANOFI PASTEUR INC. | $15,295 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2021 | |
| 2021-09-30 | Medtronic, Inc. | $749 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2021 |
| 2021-09-29 | Tandem Diabetes Care, Inc. | $1,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-09-21 | Johnson & Johnson Health Care Systems Inc. | $330 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-09-17 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-09-17 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-09-17 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-09-17 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-09-17 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-09-16 | CVRx, Inc. | $28,000 | Research payment | In-kind items and services | Barostim Neo System Device, Heart Failure and Hypertension | 2021 | |
| 2021-09-15 | CSL Behring | $25,253 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-09-15 | CSL Behring | $1,050 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-09-08 | LivaNova USA, Inc. | $1,346 | Research payment | Cash or cash equivalent | VNS - Vitaria Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2021 |
| 2021-09-01 | Surmodics, Inc. | $1,390 | Research payment | Cash or cash equivalent | SurVeil Device, drug-coated balloon | TRANSCEND | 2021 |
| 2021-08-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $9,759 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-08-27 | Genentech, Inc. | $949 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-08-26 | CSL Behring | $565 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-08-24 | Johnson & Johnson Health Care Systems Inc. | $2,245 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-08-24 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-08-23 | Johnson & Johnson Health Care Systems Inc. | $122 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-08-19 | Surmodics, Inc. | $377 | Research payment | Cash or cash equivalent | SurVeil Device, drug-coated balloon | TRANSCEND | 2021 |
| 2021-08-18 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-18 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-18 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-18 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-18 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-18 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-18 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-18 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-18 | Esperion Therapeutics, Inc. | $75 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-08-13 | CSL Behring | $14,223 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-08-13 | Genentech, Inc. | $6,000 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-08-13 | CSL Behring | $450 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-08-13 | Esperion Therapeutics, Inc. | $67 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-12 | AstraZeneca UK Limited | $8,922 | Research payment | Cash or cash equivalent | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo | 2021 | |
| 2021-08-05 | Siemens Medical Solutions USA, Inc. | $1,260 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-08-05 | Siemens Medical Solutions USA, Inc. | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ARIA Radiation Therapy Management Software Device, Oncology | 2021 | |
| 2021-08-04 | LivaNova USA, Inc. | $6,144 | Research payment | Cash or cash equivalent | VNS - Vitaria Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2021 |
| 2021-08-03 | Aesculap Implant Systems, LLC | $7,300 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-07-28 | CVRx, Inc. | $7,878 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2021 | |
| 2021-07-28 | Tandem Diabetes Care, Inc. | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-07-27 | CSL Behring | $431 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-07-26 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-07-26 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-07-26 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-20 | Esperion Therapeutics, Inc. | $39 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-16 | CSL Behring | $2,205 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-07-16 | CSL Behring | $50 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-07-13 | Medtronic, Inc. | $49 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Stroke AF | 2021 |
| 2021-07-12 | Medtronic, Inc. | $5,602 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2021 |
| 2021-07-09 | Siemens Medical Solutions USA, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SOMATOM go.Top Device, CT and RO incl. Computed Tomography and Radiation Oncology | 2021 | |
| 2021-07-07 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-07-02 | CVRx, Inc. | $35,000 | Research payment | In-kind items and services | Barostim Neo System Device, Heart Failure and Hypertension | 2021 | |
| 2021-06-30 | Medtronic, Inc. | $6,495 | Research payment | In-kind items and services | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2021 |
| 2021-06-30 | LivaNova USA, Inc. | $2,692 | Research payment | Cash or cash equivalent | VNS - Vitaria Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2021 |
| 2021-06-30 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-06-28 | Smith+Nephew, Inc. | $400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-06-25 | Amgen Inc. | $7,060 | Research payment | Cash or cash equivalent | GALACTIC - HF | 2021 | |
| 2021-06-24 | Zimmer Biomet Holdings, Inc. | $45 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2021 | |
| 2021-06-23 | Gilead Sciences, Inc. | $1,282 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2021 |
| 2021-06-23 | Gilead Sciences, Inc. | $630 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2021 |
| 2021-06-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-06-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-06-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-06-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
The latest 200 records of 441.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Greensboro, NC, county Guilford County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Greensboro, NC | County Guilford County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 301,198 | 547,940 | 10,730,404 |
| Population, 2020 census P1 | 299,035 | 541,299 | 10,439,388 |
| Median age B01002 | 34.3 | 37.5 | 39.1 |
| Under 18 B01001 | 21.7% | 22.0% | 21.8% |
| 65 and over B01001 | 14.4% | 15.9% | 17.2% |
| Households B11001 | 123,984 | 219,718 | 4,282,345 |
| Foreign born B05002 | 12.7% | 11.8% | 9.1% |
| Median household income B19013 | $61,515 | $68,642 | $72,388 |
| Median family income B19113 | $80,585 | $88,156 | $90,290 |
| Per capita income B19301 | $37,531 | $39,376 | $41,385 |
| Poverty rate B17001 | 17.0% | 14.6% | 13.0% |
| Unemployment rate B23025 | 5.1% | 4.6% | 4.7% |
| Civilian labor force B23025 | 158,568 | 282,362 | 5,336,863 |
| Mean commute (minutes) B08013 | 21.7 | 22.0 | 25.1 |
| Bachelor's degree or higher B15003 | 41.0% | 39.0% | 35.7% |
| Housing units B25001 | 135,665 | 238,032 | 4,895,668 |
| Owner-occupied B25003 | 50.5% | 59.9% | 66.6% |
| Renters B25003 | 49.5% | 40.1% | 33.4% |
| Median home value B25077 | $244,800 | $259,900 | $288,900 |
| Median gross rent B25064 | $1,172 | $1,163 | $1,228 |
| White, not Hispanic B03002 | 38.1% | 46.0% | 60.0% |
| Black B03002 | 41.0% | 33.5% | 20.0% |
| Hispanic or Latino B03002 | 10.5% | 10.1% | 11.3% |
| Asian B03002 | 5.2% | 5.4% | 3.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Greensboro, NC.
Comments